{Reference Type}: Journal Article
{Title}: Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil.
{Author}: Anselmo-Lima WT;Tamashiro E;Romano FR;Miyake MM;Roithmann R;Kosugi EM;Nakanishi M;Fornazieri MA;Bezerra TFP;Mello JF;Lessa MM;Voegels RL;Piltcher OB;Sakano E;Valera FCP;
{Journal}: Braz J Otorhinolaryngol
{Volume}: 0
{Issue}: 0
{Year}: Apr 2021 3
{Factor}: 2.474
{DOI}: 10.1016/j.bjorl.2021.03.003
{Abstract}: <B>BACKGROUND: </B>Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual's quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment.<BR><B>OBJECTIVE: </B>To review the current status of biologic treatment indications in chronic rhinosinusitis.<BR><B>METHODS: </B>The Brazilian Academy of Rhinology brought together different specialists to suggest a course of action, considering its particularities and aspects related to the national reality.<BR><B>RESULTS: </B>Of particular interest for decision making will be the identification of subgroups of patients refractory to pre-existing treatment options and the construction of a strategy that improves their quality of life, with the best cost-benefit ratio.<BR><B>CONCLUSIONS: </B>The use of biologics is a valid option for treatment in more severe cases. This strategy must be better understood and improved in the future, with more studies and greater clinical experience.